Literature DB >> 20552631

Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.

Claudia Haferlach1, Frank Dicker, Tamara Weiss, Susanne Schnittger, Christian Beck, Albert Grote-Metke, Daniel Oruzio, Wolfgang Kern, Torsten Haferlach.   

Abstract

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a variable clinical course. The aim of this study was to evaluate whether a combination of genetic parameters can improve prediction of outcome irrespective of clinical stage. The prognostic impact of chromosome banding analysis (CBA) in addition to FISH and IgVH mutation status was evaluated. In total, 482 patients were analyzed, but evaluation of prognostic factors was restricted to 399 untreated cases. The prognostic significance of age, white blood cell (WBC) count, IgVH status, and TP53 and ATM deletions was confirmed. In addition, a prognostic impact of translocations involving the IGH@ locus (t(IgH)) and of a complex aberrant karyotype was found. On the basis of these results, we propose a scoring system for overall survival (OS) based on: age >or=65 years, WBC >or=20 x 10(9)/l, unmutated IgVH status, TP53 deletion, t(IgH), and the number of chromosome aberrations observed with CBA. Three risk groups showed considerable differences in OS (94.5% vs. 64.3% vs. 41.1% surviving at 5 years, P < 0.0001). Time to treatment (TTT) can be predicted best by unmutated IgVH status, ATM deletion, t(IgH), and number of chromosome aberrations. Four distinct subgroups were separated with median TTT of 110.7 months, 39.8 months, 19.5 months, and 3.8 months, respectively (P < 0.0001). In conclusion, cytogenetic data from CBA add prognostic information. The proposed scoring systems for OS and TTT based on a combination of genetic markers improve the separation of prognostic subgroups in CLL already early in the course of the disease. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552631     DOI: 10.1002/gcc.20794

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  17 in total

1.  Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.

Authors:  Jacob D Soumerai; Ai Ni; Guan Xing; Julie Huang; Richard R Furman; Jeffrey Jones; Jeffrey P Sharman; Michael Hallek; Adeboye H Adewoye; Ronald Dubowy; Lyndah Dreiling; Andrew D Zelenetz
Journal:  Leuk Lymphoma       Date:  2018-11-08

Review 2.  The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.

Authors:  Gianluca Gaidano; Davide Rossi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile.

Authors:  I Del Giudice; G M Rigolin; S Raponi; L Cafforio; C Ilari; J Wang; M Bordyuh; A Piciocchi; M Marinelli; M Nanni; S Tavolaro; M Filetti; A Bardi; E Tammiso; E Volta; M Negrini; E Saccenti; F R Mauro; D Rossi; G Gaidano; A Guarini; R Rabadan; A Cuneo; R Foà
Journal:  Leukemia       Date:  2017-09-19       Impact factor: 11.528

Review 4.  Prognostication of chronic lymphocytic leukemia in the era of new agents.

Authors:  Barbara Eichhorst; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Sequencing of chronic lymphocytic leukemia therapies.

Authors:  Jacqueline C Barrientos
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

7.  The prognostic role of HBV infection in chronic lymphocytic leukemia.

Authors:  Jin-Hua Liang; Rui Gao; Jun-Cheng Dai; Robert Peter Gale; Wang Li; Lei Fan; Zhi-Bin Hu; Wei Xu; Jian-Yong Li
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-14       Impact factor: 4.553

8.  Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma.

Authors:  Antonella Bardi; Francesco Cavazzini; Gian Matteo Rigolin; Elisa Tammiso; Eleonora Volta; Elisa Pezzolo; Luca Formigaro; Olga Sofritti; Giulia Daghia; Cristina Ambrosio; Lara Rizzotto; Awad E Abass; Fiorella D'Auria; Pellegrino Musto; Antonio Cuneo
Journal:  J Biomed Biotechnol       Date:  2011-05-21

9.  Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation.

Authors:  Yvonne Kiefer; Christoph Schulte; Markus Tiemann; Joern Bullerdiek
Journal:  Appl Clin Genet       Date:  2012-03-12

10.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.